Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004

Clinical Colorectal Cancer

Volumn 8, Issue 3, 2009, Pages 141-145

  Cree, Marilyn ^a   Tonita, Jon ^b   Turner, Donna ^c   Nugent, Zoann ^c   Alvi, Riaz ^b   Barss, Richard ^b   King, Charlotte ^a   Winget, Marcy ^a,d  

^a Alberta Cancer Board   (Canada)

^b SASKATCHEWAN CANCER AGENCY   (Canada)

^c CANCERCARE MANITOBA   (Canada)

^d NONE   (Canada)

Author keywords

Adjuvant treatment; Health services research; Quality of care; Treatment guidelines

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; COLON CANCER; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GEOGRAPHIC DISTRIBUTION; GOOD CLINICAL PRACTICE; HEALTH SERVICES RESEARCH; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RECTUM CANCER; RESIDENTIAL CARE; SEX DIFFERENCE;

EID: 69549085138     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2009.n.023     Document Type: Article

References (45)

1. American Society of Clinical Oncology [Web site]. Available at: http://www.ascocancerfoundation.org/patient/Cancer+Types/Colorectal+Cancer. Accessed: June 9, 2008.
2. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7:1447-1456
3. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352-358 (Pubitemid 20042739)
4. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264:1444-1450
5. Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 1997; 40:35-41. (Pubitemid 27056396)
6. Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007; 25:4569-4574 (Pubitemid 350035314)
7. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23:8664-8670
8. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345:939-944
9. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324:709-715
10. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer [summary for patients in Med J Aust 2002; 177:563-4]. N Engl J Med 2001; 345:638-646
11. Glynne-Jones R, Grainger J, Harrison M, et al. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? Br J Cancer 2006; 94:363-371 (Pubitemid 43237561)
12. Chua YJ, Cunningham D. Emerging therapies for rectal cancer. Colorectal Dis 2006; 8(suppl 3):18-20.
13. Chau I, Allen M, Cunningham D, et al. Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. Br J Cancer 2003; 88:1017-1024 (Pubitemid 36560768)
14. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. [see comment] J Clin Oncol 2006; 24:668-674 (Pubitemid 46630432)
15. Collette L, Bosset J-F, den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25:4379-4386 (Pubitemid 350013843)
16. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731-1740 (Pubitemid 39383208)
17. Arnoletti JP, Bland KI. Neoadjuvant and adjuvant therapy for rectal cancer. Surg Oncol Clin N Am 2006; 15:147-157 (Pubitemid 43017761)
18. McFall SL, Warnecke RB, Kaluzny AD, et al. Practice setting and physician influences on judgments of colon cancer treatment by community physicians. Health Serv Res 1996; 31:5-19. (Pubitemid 26155839)
19. Bryson GL, Wyand A, Bragg PR. Preoperative testing is inconsistent with published guidelines and rarely changes management. Can J Anaesth 2006; 53:236-241
20. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997; 157:408-416 (Pubitemid 27384745)
21. Rabeneck L, Davila JA, Thompson M, et al. Outcomes in elderly patients following surgery for colorectal cancer in the veterans affairs health care system. Aliment Pharmacol Ther 2004; 20:1115-1124 (Pubitemid 39657945)
22. Dominitz JA, Samsa GP, Landsman P, et al. Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer 1998; 82:2312-2320 (Pubitemid 28283436)
23. Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93:850-857 (Pubitemid 32590779)
24. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998; 82:2123-2134 (Pubitemid 28240818)
25. Hamel MB, Teno JM, Goldman L, et al. Patient age and decisions to withhold life-sustaining treatments from seriously ill, hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. Ann Intern Med 1999; 130:116-125
26. Oliveria SA, Yood MU, Campbell UB, et al. Treatment and referral patterns for colorectal cancer. Med Care 2004; 42:901-906 (Pubitemid 39456922)
27. Harris R, Leininger L. Preventive care in rural primary care practice. Cancer 1993; 72:1113-1118 (Pubitemid 23218036)
28. Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994; 86:1766-1770 (Pubitemid 24373451)
29. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993; 85:1580-1584 (Pubitemid 23304686)
30. Kemeny N. Colorectal cancer-an undertreated disease. Anticancer Drugs 1996; 7:623-629
31. Weeks JC. Preferences of older cancer patients: can you judge a book by its cover? J Natl Cancer Inst 1994; 86:1743-1744
32. Statistics Canada [Web site]. Available at: http://www12.statcan.ca/ english/census06/data/popdwell/Table.cfm?T=101. Accessed: July 8, 2009.
33. Winget M, Turner D, Tonita J, et al. Across-province standardization and comparative analysis of time-to-care intervals for cancer. BMC Cancer 2007; 7:186. (Pubitemid 350162828)
34. Cancer AJCo. AJCC Cancer Staging Manual (Sixth Edition). New York: Springer-Verlag, 2002.
35. Tucker TC, Howe HL, Weir HK. Certification for Population-based Cancer Registries. Journal of Registry Management 1999; 26:24-27
36. Fritz A, Percy C. International Classification of Disease for Oncology. 3rd ed. World Health Organization; Lyon: 2000.
37. Jessup JM, McGinnis LS, Steele GD, Jr, et al. The National Cancer Data Base. Report on colon cancer. Cancer 1996; 78:918-926 (Pubitemid 26268626)
38. Jessup JM, Stewart AK, Menck HR. The National Cancer Data Base report on patterns of care for adenocarcinoma of the rectum, 1985-1995. Cancer 1998; 83:2408-2418
39. Jessup JM, Stewart A, Greene FL, et al. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005; 294:2703-2711 (Pubitemid 41770099)
40. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 2003; 21:1293-1300
41. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncoloty. Rectal Cancer - Version 1. 2008. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/rectal.pdf
42. Figueredo A, Wong RK, Agboola O, et al, and members of the Gastrointestinal Cancer Disease Site Group. The Use of Preoperative Radiotherapy in the Management of Patients with Clinically Resectable Rectal Cancer Practice Guideline Report #2-13, in Ontario CC (ed): Program in evidence-based care. Available at: http://www.cancercare.on.ca/pdf/pebc2-13s.pdf. Accessed: June 9, 2008.
43. Seymour MT, Stenning SP, Cassidy J. Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. Clin Oncol (R Coll Radiol) 1997; 9:248-251
44. Muss HB, Cohen HJ, Lichtman SM. Clinical research in the older cancer patient. Hematol Oncol Clin North Am 2000; 14:283-291 (Pubitemid 30078443)
45. Mandelblatt JS, Yabroff KR, Kerner JF. Equitable access to cancer services: A review of barriers to quality care. Cancer 1999; 86:2378-2390